BGNE Teams Up With NVS, Editas Slumps Over 15%, LLY's Drug Shines In TRAILBLAZER-ALZ, MESO On Watch

RTT News

by Super Admin 116 Views

Today's Daily Dose brings you news about Lilly's Alzheimer's disease trial data, BeiGene's collaboration agreement with Novartis, Mesoblast's encouraging results from phase III trial of Rexlemestrocel-L in patients with chronic heart failure, and the resignation of Editas' Chief Scientific Officer.